Framework Journal · one stock, one dated entry

Recorded 2026-07-19 · Permanent

Jyong Biotech Ltd MENS

Clears both ethical standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia.

The label
Accumulation

read at $2.26

Jyong Biotech Ltd holds its Accumulation at $2.26.

PHINPOOPSC
  • PHPhase · the trend structure carries the Accumulation label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · passes the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2026-07-19
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 92 days
Price$2.26
ValuationN/A trailing · N/A forward price to earnings
Values screenPASS · score 70.0
BetaN/A

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Profit margin0.0%
currently unprofitable
Current ratio0.45
below 1 — short-term bills exceed liquid assets
Market cap$172M
Employees27

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Taiwan and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in MENS's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 22%. Entered 2026-07-18 · Accumulation

The dated journal · newest first, never edited

2026-07-18 Accumulation $1.58 +0.0% Entry 3

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 22%.

2026-07-03 Accumulation $1.58 +0.0% Entry 2

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Accumulation $1.58 Entry 1

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The political ledger · congressional disclosures

Disclosures naming MENS
DatePoliticianPartyTypeAmount
8 May2026 Ro Khanna Democrat buy 1K–15K

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $2.07 -16.9% · $831 -16.9%
2 months $2.49 -30.9% · $691 -30.9%
3 months $2.15 -20.0% · $800 -20.0%
6 months $26.64 -93.5% · $65 -93.5%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever MENS does next, these words stay.

Jyong Biotech Ltd · MENS · Accumulation · $2.26
Recorded 2026-07-19 · before the outcome · scored mechanically

Get our weekly market brief free.